Investigation of survival and prognostic factors in triple negative molecular subtype male breast cancer patients: A population-based study

• Published in: Medicine science 2024, Vol.13 (4), p.829
• Main Authors: Sanli, Ahmet, Turan, Bilal
• Format: Article
• Language: English
• ISSN: 2147-0634; 2147-0634
• DOI: 10.5455/medscience.2024.06.056

In this study, it was aimed to investigate the survival rate and prognostic factors affecting survival in triple negative male breast cancer patients. Data were obtained from SEER (Surveillance Epidemiology and End Results). Triple-negative male breast cancer patients between 2010 and 2019 were included in the study. Demographic, clinical, and oncology data were evaluated. Among 4930 male breast cancer patients, 92 (1.87%) patients with triple negative molecular subtypes were included in the study. The median age of the patients was 67 (IQR: 58.25-73.5). The majority of the patients were white (68.5%). The rate of being married was 62%. It was on both sides; the most common tumor localization was upper outer quadrant and central, respectively. The most common grades were III-IV (66.3%). The most common stages were T2 (44.6%) in the T stage and N0 (54%) in the N stage. The most common stage was IV (28.3%). Mean follow-up time was 25.76±25.02, and overall survival was 50.5% and cancer specific survival was 59.6%. Grade, metastasis status, and surgical status were found to be independent risk factors for survival. The majority of triple negative male breast cancer patients were in advanced stages, and survival rates were low. It is encouraging that triple negative molecular subtype breast cancer, which is an aggressive tumor, is less common in men.